Apr. 8 at 4:06 PM
$ORMP The market appears to be completely oblivious to what is happening with this company. ORMP has worked with its Chinese partner for years. The partner has filed with the Chinese regulator for approval. This filing is obviously based upon the "failed" phase 3 results in ORMP's US trial and the post hoc analysis in which ORMP determined that the tech works for a subgroup of patients having known biological characteristics. The Chinese partner knows that the Chinese regulator will accept it. Also, the partner obviously expects that it will be approved. Thus, ORMP is about to prove to the world that its tech actually works, even though the US stock market obviously believes that it does not work, because it failed phase 3. The partner is putting up serious cash. Meanwhile, the market cap of ORMP is less than its cash holdings, i.e. there is no value to the tech in its market cap. What happens when the market realizes that the tech works? I think this stock is seriously under valued.
